Home
>
US Stocks
>
Allied World Assurance Company Holdings

Allied World Assurance Company Holdings (AWH)

$2.99

+0.01

(+0.34%)▲

Market is closed - opens 7 PM, 06 Jun 2023

Insights on Allied World Assurance Company Holdings

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 6.11M → 2.31M (in $), with an average decrease of 62.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -22.61M → -6.06M (in $), with an average increase of 272.7% per quarter

  • Vs IDXX

    In the last 1 year, Idexx Laboratories, Inc. has given 25.0% return, outperforming this stock by 90.8%

  • Vs IDXX

    In the last 3 years, Idexx Laboratories, Inc. has given 49.3% return, outperforming this stock by 66.2%

Performance

  • $2.95
    $3.06
    $2.99
    downward going graph

    1.51%

    Downside

    Day's Volatility :3.76%

    Upside

    2.29%

    downward going graph
  • $2.82
    $247.50
    $2.99
    downward going graph

    5.69%

    Downside

    52 Weeks Volatility :98.86%

    Upside

    98.79%

    downward going graph

Returns

PeriodAllied World Assurance Company HoldingsSector (Health Care)Index (Russel 2000)
3 Months
-59.84%
1.3%
-6.9%
6 Months
-46.13%
-4.8%
-2.4%
1 Year
-65.84%
0.7%
-6.4%
3 Years
-22.54%
26.7%
17.4%

Highlights

Market Capitalization
24.8M
Book Value
$0.1
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.73
PEG Ratio
0.0
Wall Street Target Price
4.5
Profit Margin
-278.48%
Operating Margin TTM
-340.27%
Return On Assets TTM
-86.43%
Return On Equity TTM
-212.39%
Revenue TTM
8.6M
Revenue Per Share TTM
1.08
Quarterly Revenue Growth YOY
22.3%
Gross Profit TTM
4.3M
EBITDA
-29.0M
Diluted Eps TTM
-2.73
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.76
EPS Estimate Next Year
-1.27
EPS Estimate Current Quarter
-0.05
EPS Estimate Next Quarter
-0.04

Analyst Recommendation

Sell
    0
    0%Buy
    44%Hold
    55%Sell
Based on 9 Wall street analysts offering stock ratings for Allied World Assurance Company Holdings(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
4
4
4
Sell
5
5
5

Analyst Forecast

What analysts predicted

Upside of 50.5%

Current $2.99
Target $4.50

Company Financials

FY17Y/Y Change
Revenue
3.1M
↑ 18.13%
Net Income
-10.5M
↓ 29.87%
Net Profit Margin
-336.33%
↑ 230.21%
FY18Y/Y Change
Revenue
3.1M
↓ 2.18%
Net Income
-11.4M
↑ 8.33%
Net Profit Margin
-372.45%
↓ 36.12%
FY19Y/Y Change
Revenue
4.5M
↑ 48.64%
Net Income
-15.2M
↑ 34.0%
Net Profit Margin
-335.76%
↑ 36.69%
FY20Y/Y Change
Revenue
4.7M
↑ 2.49%
Net Income
-17.9M
↑ 17.51%
Net Profit Margin
-384.97%
↓ 49.21%
FY21Y/Y Change
Revenue
6.8M
↑ 46.46%
Net Income
-31.7M
↑ 76.83%
Net Profit Margin
-464.8%
↓ 79.83%
FY22Y/Y Change
Revenue
8.2M
↑ 20.14%
Net Income
-27.2M
↓ 14.19%
Net Profit Margin
-331.99%
↑ 132.81%
Q4 FY21Q/Q Change
Revenue
1.9M
↑ 11.1%
Net Income
-9.0M
↓ 7.69%
Net Profit Margin
-484.12%
↑ 98.53%
Q1 FY22Q/Q Change
Revenue
1.9M
↑ 2.27%
Net Income
-9.3M
↑ 3.43%
Net Profit Margin
-489.59%
↓ 5.47%
Q2 FY22Q/Q Change
Revenue
2.1M
↑ 9.14%
Net Income
-8.2M
↓ 11.06%
Net Profit Margin
-398.98%
↑ 90.61%
Q3 FY22Q/Q Change
Revenue
2.1M
↑ 0.29%
Net Income
-4.6M
↓ 44.7%
Net Profit Margin
-219.98%
↑ 179.0%
Q4 FY22Q/Q Change
Revenue
6.1M
↑ 194.98%
Net Income
-22.6M
↑ 396.09%
Net Profit Margin
-369.96%
↓ 149.98%
Q1 FY23Q/Q Change
Revenue
2.3M
↓ 62.11%
Net Income
-6.1M
↓ 73.17%
Net Profit Margin
-261.96%
↑ 108.0%
FY17Y/Y Change
Total Assets
7.5M
↓ 6.51%
Total Liabilities
4.1M
↓ 3.92%
FY18Y/Y Change
Total Assets
11.4M
↑ 52.17%
Total Liabilities
4.3M
↑ 4.06%
FY19Y/Y Change
Total Assets
13.8M
↑ 21.21%
Total Liabilities
5.1M
↑ 19.6%
FY20Y/Y Change
Total Assets
19.6M
↑ 41.78%
Total Liabilities
9.9M
↑ 94.22%
FY21Y/Y Change
Total Assets
41.1M
↑ 109.53%
Total Liabilities
10.9M
↑ 10.33%
FY22Y/Y Change
Total Assets
17.4M
↓ 57.71%
Total Liabilities
10.6M
↓ 2.43%
Q4 FY21Q/Q Change
Total Assets
41.1M
↓ 14.5%
Total Liabilities
10.9M
↑ 14.29%
Q1 FY22Q/Q Change
Total Assets
30.9M
↓ 24.87%
Total Liabilities
9.1M
↓ 16.41%
Q2 FY22Q/Q Change
Total Assets
24.0M
↓ 22.18%
Total Liabilities
9.9M
↑ 8.52%
Q3 FY22Q/Q Change
Total Assets
23.9M
↓ 0.31%
Total Liabilities
12.8M
↑ 29.01%
Q4 FY22Q/Q Change
Total Assets
17.4M
↓ 27.44%
Total Liabilities
10.6M
↓ 16.62%
Q1 FY23Q/Q Change
Total Assets
11.5M
↓ 33.83%
Total Liabilities
10.7M
↑ 0.25%
FY17Y/Y Change
Operating Cash Flow
-8.1M
↓ 41.78%
Investing Cash Flow
-60.0K
↓ 95.24%
Financing Cash Flow
8.5M
↑ 365.24%
FY18Y/Y Change
Operating Cash Flow
-9.4M
↑ 15.23%
Investing Cash Flow
-113.0K
↑ 88.33%
Financing Cash Flow
13.3M
↑ 56.74%
FY19Y/Y Change
Operating Cash Flow
-13.0M
↑ 38.42%
Investing Cash Flow
-132.0K
↑ 16.81%
Financing Cash Flow
15.4M
↑ 16.09%
FY20Y/Y Change
Operating Cash Flow
-14.7M
↑ 13.64%
Investing Cash Flow
-490.0K
↑ 271.21%
Financing Cash Flow
20.2M
↑ 30.51%
FY21Y/Y Change
Operating Cash Flow
-27.4M
↑ 85.93%
Investing Cash Flow
-184.0K
↓ 62.45%
Financing Cash Flow
48.4M
↑ 140.07%
Q4 FY21Q/Q Change
Operating Cash Flow
-7.6M
↓ 4.4%
Investing Cash Flow
-30.0K
↑ 66.67%
Financing Cash Flow
-11.0K
↓ 107.53%
Q1 FY22Q/Q Change
Operating Cash Flow
-10.2M
↑ 33.0%
Investing Cash Flow
-82.0K
↑ 173.33%
Financing Cash Flow
-70.0K
↑ 536.36%
Q2 FY22Q/Q Change
Operating Cash Flow
-6.3M
↓ 38.03%
Investing Cash Flow
-23.0K
↓ 71.95%
Financing Cash Flow
-48.0K
↓ 31.43%
Q3 FY22Q/Q Change
Operating Cash Flow
-8.6M
↑ 36.93%
Investing Cash Flow
-53.0K
↑ 130.43%
Financing Cash Flow
8.8M
↓ 18341.67%

Technicals Summary

Sell

Neutral

Buy

Allied World Assurance Company Holdings is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Allied World Assurance Company Holdings
Allied World Assurance Company Holdings
-34.77%
-46.13%
-65.84%
-22.54%
199.06%
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
-4.17%
12.01%
25.0%
50.25%
111.96%
Agilent Technologies Inc.
Agilent Technologies Inc.
-10.65%
-21.8%
-7.27%
31.08%
81.55%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-4.42%
-5.8%
-6.2%
48.22%
137.59%
Danaher Corp.
Danaher Corp.
-2.56%
-12.15%
-11.61%
35.92%
126.77%
IQVIA Holdings Inc.
IQVIA Holdings Inc.
7.48%
-2.79%
-7.6%
36.01%
96.75%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Allied World Assurance Company Holdings
Allied World Assurance Company Holdings
NA
NA
0.0
-1.76
-2.12
-0.86
0.0
0.1
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
55.85
55.85
7.21
9.69
0.94
0.22
0.0
10.13
Agilent Technologies Inc.
Agilent Technologies Inc.
25.98
25.98
2.36
5.61
0.25
0.1
0.01
19.58
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
33.91
33.91
4.28
23.68
0.14
0.05
0.0
109.55
Danaher Corp.
Danaher Corp.
25.07
25.07
3.24
8.75
0.14
0.06
0.0
68.31
IQVIA Holdings Inc.
IQVIA Holdings Inc.
35.33
35.33
1.48
10.42
0.18
0.05
0.0
31.98
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Allied World Assurance Company Holdings
Allied World Assurance Company Holdings
Sell
$24.8M
199.06%
NA
-278.48%
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
Buy
$39.1B
111.96%
55.85
20.38%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$34.9B
81.55%
25.98
19.19%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$200.6B
137.59%
33.91
13.75%
Danaher Corp.
Danaher Corp.
Buy
$173.1B
126.77%
25.07
22.4%
IQVIA Holdings Inc.
IQVIA Holdings Inc.
Buy
$37.4B
96.75%
35.33
7.28%

Institutional Holdings

  • Vanguard Group Inc

    2.18%

  • BlackRock Inc

    0.79%

  • Oracle Investment Management Inc

    0.58%

  • TOWNSQUARE CAPITAL LLC

    0.55%

  • National Asset Management Inc

    0.53%

  • Sabby Management LLC

    0.48%

Corporate Announcements

  • Allied World Assurance Company Holdings Earnings

    Allied World Assurance Company Holdings’s price-to-earnings ratio stands at None

    Read More

Company Information

vermillion, inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. the company’s initial in vitro diagnostic test, ova1®, was the first fda-cleared, protein-based in vitro diagnostic multivariate index assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. in march 2016 vermillion received fda clearance for overa™, a second generation ova1 test with significantly improved specificity and ease of use.

Organization
Allied World Assurance Company Holdings
Employees
85
CEO
Ms. Valerie Barber Palmieri
Industry
Health Technology

Discover More

FAQs